Supernus Announces First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Supernus Pharma (SUPN) Misses Q1 EPS by 13c, Revenues Beat; Offers FY21 Revenues Outlook
May 5, 2021 4:55 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.11, $0.13 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $130.9 million versus the consensus estimate of $129.2 million.
The approval of Qelbree provides pediatric patients living with ADHD a therapy with proven... More
